Heart Risk Could be Increased by Hormone Therapy, Research Says

HeartAmerican researchers recently revealed that analyses from the Women's Health Initiative have confirmed that combination hormone therapy could end up substantially increasing the risk of heart diseases.

A team of experts from the Harvard School of Public Health and the National Heart, Lung and Blood Institute once again studied and analyzed the data collected through the landmark Women's Health Initiative clinical trial of the effects of combination hormone therapy, which is when women are given progestin in combination with estrogen, in as many as 16,608 post-menopausal women with uteruses which were still intact. The women were all between the ages of 50 and 79.

The research led the experts to discover a trend towards an increased risk of cardiovascular diseases during the initial 2 years of the therapy among women who were put on it within 10 years of menopause. The risk was even more in women who started the therapy more than 10 years after hitting menopause.

"Today, most women who take hormone therapy for menopausal symptoms begin therapy shortly after menopause. Based on today's report, even these women appear to be at increased risk of heart disease for several years after starting combination hormone therapy", said Dr. Susan B. Shurin, acting director of the National Heart, Lung, and Blood Institute.

Details of the study have been published in the Annals of Internal Medicine.